Synonyms: compound 1 [US2022257577] | CPI 0209 | CPI-0209 | CPI0209
Compound class:
Synthetic organic
Comment: Tulmimetostat (CPI-0209) is an orally bioavailable and selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2) [2], that was designed for anti-tumour potential. Expression of EZH2 in cancers is associated with progression, stem cell self-renewal, migration and angiogenesis.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Tulmimetostat (CPI-0209) has advanced to early stage clinical evaluation. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04104776 | A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas | Phase 1/Phase 2 Interventional | Constellation Pharmaceuticals |